This investment trust invests in companies that are active in the biotechnology sector.
From todays Daily Mail
International Biotechnology Trust (IBT) could be an interesting Isa addition at this point in the cycle. It has been hard-hit by Trump’s tariffs in recent weeks and probably shouldn’t take the whole allocation of someone making their first Isa investment, but it could be a decent addition to a more diversified set of investments.
IBT is managed by Ailsa Craig and Marek Poszepczynski, who have delivered strong returns since taking over around four years ago, outperforming in rising and falling markets.
They take a risk-aware approach, not over-committing to single companies in therapeutic areas but spreading the risk across a few ideas.
They have currently positioned the portfolio in smaller companies in anticipation of rising M&A this year. If US rates fall over the next year or two, it could really set this market off. IBT is another trust trading on a decent discount (c. 11 per cent at the time of writing) and with significant gearing, adding to the return potential.
Marked it on my watchlist for a future buy